Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes

Messika–Zeitoun, David; Nickenig, Georg; Latib, Azeem; Kuck, Karl Heinz; Baldus, Stephan; Schueler, Robert; Canna, Giovanni La; Agricola, Eustachio; Kreidel, Felix; Huntgeburth, Michael; Züber, Michel; Verta, Patrick; Grayburn, Paul A.; Vahanian, Alec; Maisano, Francesco

doi:10.1093/eurheartj/ehy424

Cited by 146 publications

(109 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent publication reported 1-year outcomes after Cardioband implantation in 60 patients with moderate or severe secondary MR treated in 11 European institutions. While 30-day mortality was below 5%, the MVARC-defined procedural success was only of 68%, more than mild MR remained after the procedure in 30% of patients, reintervention was frequent during the 1-year follow-up [23,24]. These data were consistent of those published on short term outcomes.…”

Section: Transcatheter Annuloplasty and Chordal Plastysupporting

confidence: 87%

Advances in transcatheter mitral and tricuspid therapies

Overtchouk

Piazza

Granada

et al. 2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background: While rheumatic mitral stenosis has been effectively treated percutaneously for more than 20 years, mitral and tricuspid regurgitation treatment appear as a contemporary unmet need. The advent of transcatheter therapies offer new treatment options to often elderly and frail patients at high risk for open surgery. We aimed at providing an updated review of fast-growing domain of transcatheter mitral and tricuspid technology. Main body: We reviewed the existing literature on mitral and tricuspid transcatheter therapies. Mitraclip is becoming an established therapy for secondary mitral regurgitation in selected patients with disproportionately severe regurgitation associated with moderate left ventricle dysfunction. Evidence is less convincing for primary mitral regurgitation. Transcatheter mitral valve replacement is a promising emerging alternative to transcatheter repair, for secondary as well as primary mitral regurgitation. But further development is needed to improve delivery. Transcatheter tricuspid intervention arrives late after similar technologies have been developed for aortic and mitral valves and is currently at its infancy. This is likely due in part to previously under-recognized impact of tricuspid regurgitation on patient outcomes. Edge-to-edge repair is the most advanced transcatheter solution in development. Data on tricuspid annuloplasty and replacement is limited, and more research is warranted. Conclusion: The future appears bright for transcatheter mitral therapies, albeit their place in clinical practice is yet to be clearly defined. Tricuspid transcatheter therapies might address the unmet need of tricuspid regurgitation treatment.

show abstract

Section: Transcatheter Annuloplasty and Chordal Plastysupporting

confidence: 87%

Advances in transcatheter mitral and tricuspid therapies

Overtchouk

Piazza

Granada

et al. 2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“…Since the first‐in‐man implantation of the cardioband, a few studies have reported safety, efficacy and the short‐term results of the technique 5,6 . In a multicenter study, Zeitoun et al reported 1 year outcomes of the system with a technical success rate of 97%.…”

Section: Discussionmentioning

confidence: 99%

Surgical explantation of a partially detached cardioband device

et al. 2020

View full text Add to dashboard Cite

Transcatheter repair systems are becoming increasingly popular as a potential solution for high‐risk and inoperable patients with mitral regurgitation. The cardioband (Edwards Lifesciences, Irvine, California) is a transcatheter direct annuloplasty device, based on the concept of an undersized ring annuloplasty. We report a case of minimally invasive surgical explantation of a failed cardioband device 21 months after its implantation. Intraoperatively, it was found that three anchors of the cardioband device were detached from the posterior annulus at P2. In this report, a “cut and unscrew” technique with some tips and tricks is presented for the removal of the device.

show abstract

“…In einer ersten multizentrischen Beobachtungsstudie mit einer Nachbeobachtung von einem Jahr bestätigten sich die erfolgversprechenden Ergebnisse. Von den beobachteten 61 Patienten wiesen nach einem Jahr 61 % eine residuale MI ≤ 2 auf [18]. Die meisten Patienten fanden sich in der NYHA-Klasse 1 oder 2.…”

Section: Interventionelle Therapieoptionenunclassified